newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - CORBUS PHARMACEUTICALS HOLDINGS INC

  • Financial Performance:

    • No specific financial metrics (revenue, profit margins, cash flow, or debt) were disclosed; the company is described as a pre-revenue biotech with approximately 40 employees based in Norwood, Massachusetts.
  • Guidance and Future Outlook:

    • The Biologics License Application (BLA) for the oncology asset (Nectin-4 ADC) is expected in the second half of 2028, contingent on robust ORR data and follow-up by the first half of 2026.
    • Management anticipates the Phase 3 TEMPO-1 trial (second-line head and neck cancer) to wrap up relatively shortly due to the accelerated approval pathway.
    • The obesity asset (CB1 inverse agonist) expects long-term efficacy data (52 weeks) comparable to Monolaural Band (Orforglipron), projecting weight loss between 10% and 12% at one year.
    • Potential expansion into the front-line setting for the oncology asset is anticipated, though timing depends on competitor data.
  • Business Segments and Product Lines:

    • Oncology (Nectin-4 ADC/Sutantitag vedotin): Currently in Phase 3 (TEMPO-1) for second-line oropharyngeal cancer; earlier Phase 1/2 data showed responses in both HPV-positive and HPV-negative patients.
    • Obesity (CB1 Inverse Agonist): Completed a Phase 1b study with 250 patients; presented at Obesity Week showing efficacy similar to oral GLP-1s with a distinct mechanism.
    • Partnerships: CSBC (China) is launching a Phase 3 in cervical cancer using a slightly different dosing regimen (2.4 mg Q2W) mandated by the Chinese FDA, while the bladder cancer program retains the 3.6 mg Q3W regimen.
    • Naming: The Nectin-4 ADC has received the official name "sutantitag vedotin."
  • Market and Competitive Landscape:

    • Competitive Strategy: Management plans to emulate the Genmab (GenMap) strategy, focusing on dual primary endpoints (ORR for accelerated approval, OS for full approval).
    • Head-to-Head with Peto (Padcev): Peto is positioned as a front-line drug; this removes competitive pressure in the second-line setting where Corbus operates, as Peto's second-line data is not expected to be commercially viable or FDA approved soon.
    • Competitor Analysis:
      • Pixys (MX): Targets the HPV-negative population; Corbus notes their mechanisms differ significantly, with Corbus focusing on Nectin-4 expression in oropharyngeal tumors.
      • BMS/Regeneron (Tivdak/Padsev): Used as benchmarks for ocular toxicity management in ADCs.
    • Unmet Need: The second-line oropharyngeal market is described as a "desert" with poor options (primarily chemotherapy), presenting a significant commercial opportunity.
    • Front-line Outlook: To coexist with Peto in the front line, Corbus aims for an ORR >50% in HPV-positive patients to establish a meaningful efficacy delta.
  • Risks and Challenges:

    • Ocular Toxicity: The ADC class is associated with keratitis and dry eye; while manageable with early intervention (eye drops/dose interruptions), it remains a key safety consideration.
    • HPV Status Dilution: Inclusion of HPV-negative patients (approx. 15% of the population) could potentially dilute treatment effects, though data shows value in this subgroup as well.
    • Regulatory Uncertainty: Future front-line competition from Peto's potential oral pharyngeal agnostic label depends on Peto's upcoming data.
    • Psychiatric Events: Mild, transient irritability was observed in the obesity program, resolving upon discontinuation and not causing dose-dependent issues or study drops.
  • Management Commentary and Tone:

    • Confidence: Management expressed high confidence in the statistical assumptions and alignment with FDA expectations, citing the "sensible" and "enviable" nature of the GenMap strategy.
    • Strategic Clarity: The CEO emphasized the strategic advantage of focusing on oropharyngeal cancer (85% HPV+ baseline) rather than HPV status as a primary inclusion criterion, allowing for a broader real-world applicable label.
    • Optimism: Tone regarding the obesity program was enthusiastic regarding KOL feedback, efficacy potential, and the orthogonal mechanism compared to existing GLP-1s.
  • Analyst Questions and Answers:

    • Statistical Assumptions: Management confirmed the control arm ORR is assumed around 20% and the treatment arm target is >30% for second-line (and >50% for front-line) to be clinically actionable.
    • HPV Stratification: Discussion confirmed that while P16 testing is standard for retrospective stratification, the trial population is anatomically defined (oropharyngeal) to avoid artificial skewing.
    • Dosing Regimen: Explained that the Chinese partner's shift to 2.4 mg Q2W in cervical cancer is a specific FDA peculiarity, as their data showed the 3.6 mg Q3W regimen (used elsewhere) is equally effective.
    • Safety Management: Clarified that ocular toxicity in ADCs is distinct from peripheral neuropathy, is usually resolvable, and follows a "wave" pattern manageable by standard protocols.
  • Other Key Points:

    • The company operates as a small, specialized biotech with a unique dual-asset pipeline unrelated to each other.
    • The obesity asset utilizes a "peripherally restricted" mechanism to minimize central nervous system side effects.
    • Management highlighted that the lack of effective second-line therapies in oropharyngeal cancer is a "medical tragedy" that their drug aims to address immediately.
Company
CORBUS PHARMACEUTICALS HOLDINGS INC
Keywords
CORBUS PHARMACEUTICALS HOLDINGS INC